ConductScience.org, home

Paper37339170

A Nonconserved Histidine Residue on KRAS Drives Paralog Selectivity of the KRASG12D Inhibitor MRTX1133.

Keats MA and 4 others. Cancer Res, 2023. Cited by 21 papers, by iCite.

Cite this record

ConductScience Library. A Nonconserved Histidine Residue on KRAS Drives Paralog Selectivity of the KRASG12D Inhibitor MRTX1133. Papers, record 37339170. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37339170

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A Nonconserved Histidine Residue on KRAS Drives Paralog Selectivity of the KRASG12D Inhibitor MRTX1133.
PubMed
Journal
Cancer Res
PubMed
Year
2023
PubMed
Publication types
Journal Article, Research Support, N.I.H., Intramural
PubMed
Citations, by iCite
21
iCite
Relative citation ratio, by iCite
1.52
iCite
Revised in PubMed
2026-01-27
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
HistidineMajor topic
Proto-Oncogene Proteins p21(ras)Major topic
Humans
Mutation
Cell Line
Heterocyclic Compounds, 2-Ring
Naphthalenes

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
ZIA BC011732Intramural NIH HHSUnited StatesZIABC011732PubMed and NIH

Source NIH RePORTER

Download CSV of grants

References15

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136115844Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma.Nat Commun2022https://conductscience.org/library/papers/36115844PubMed
223103856Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling.Cancer Discov2013https://conductscience.org/library/papers/23103856PubMed
334889605Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor.J Med Chem2022https://conductscience.org/library/papers/34889605PubMed
434096690Sotorasib for Lung Cancers with KRAS p.G12C Mutation.N Engl J Med2021https://conductscience.org/library/papers/34096690PubMed
535658005Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.N Engl J Med2022https://conductscience.org/library/papers/35658005PubMed
631658955The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.Cancer Discov2020https://conductscience.org/library/papers/31658955PubMed
736216931Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor.Nat Med2022https://conductscience.org/library/papers/36216931PubMed
834161704Acquired Resistance to KRASG12C Inhibition in Cancer.N Engl J Med2021https://conductscience.org/library/papers/34161704PubMed
924256730K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.Nature2013https://conductscience.org/library/papers/24256730PubMed
1020150892Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival.EMBO J2010https://conductscience.org/library/papers/20150892PubMed
1133824136Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation.Cancer Discov2021https://conductscience.org/library/papers/33824136PubMed
1232250617Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer.J Med Chem2020https://conductscience.org/library/papers/32250617PubMed
1321993244RAS oncogenes: weaving a tumorigenic web.Nat Rev Cancer2011https://conductscience.org/library/papers/21993244PubMed
1431666701The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.Nature2019https://conductscience.org/library/papers/31666701PubMed
1536472553Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer.Cancer Discov2023https://conductscience.org/library/papers/36472553PubMed

Download CSV of references

Cited by18

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 21 citations.

PMIDTitleJournalYearIn PapersSource
42818643Chemical Genetic Targeting of the LRRK2 GTPase Domain.bioRxiv2026https://conductscience.org/library/papers/42818643PubMed
42587080Brønsted-basic small molecules activate GTP hydrolysis in KRAS-Q61 mutants.Nat Chem Biol2026https://conductscience.org/library/papers/42587080PubMed
42365569Benchmarking docking and ML re-scoring screening performance for KRAS G12D in pancreatic cancer.Mol Divers2026https://conductscience.org/library/papers/42365569PubMed
42209458Efficacy of dual KRASG12D-EGFR blockade versus triple combinations in patient-derived models of KRASG12D-mutant colorectal cancer.Cell Death Dis2026https://conductscience.org/library/papers/42209458PubMed
41969551Emerging KRAS G12D inhibitor in the treatment of digestive system tumors: opportunities and challenges.Transl Gastroenterol Hepatol2026https://conductscience.org/library/papers/41969551PubMed
41827015Systematic and precise interventions for KRAS-mutant cancers.Exp Hematol Oncol2026https://conductscience.org/library/papers/41827015PubMed
41801133Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition.Clin Cancer Res2026https://conductscience.org/library/papers/41801133PubMed
41129140Dual Inhibitors of KRASG12D and HSP90 Are Effective against KRASG12D Inhibitor Resistance.Mol Cancer Ther2026https://conductscience.org/library/papers/41129140PubMed
40824523Novel paradigms in KRAS targeting: Unveiling strategies to combat drug resistance.Chin Med J (Engl)2025https://conductscience.org/library/papers/40824523PubMed
40146324Enhancing KRAS G12D inhibitor sensitivity in pancreatic cancer through SHP2/PI3K pathway.Med Oncol2025https://conductscience.org/library/papers/40146324PubMed
40140597A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers.BJC Rep2025https://conductscience.org/library/papers/40140597PubMed
39975043De novo design of Ras isoform selective binders.bioRxiv2025https://conductscience.org/library/papers/39975043PubMed
39732595KRAS inhibitors: resistance drivers and combinatorial strategies.Trends Cancer2025https://conductscience.org/library/papers/39732595PubMed
38686056Targeting KRAS in pancreatic cancer.Oncol Res2024https://conductscience.org/library/papers/38686056PubMed
38443470Strain-release alkylation of Asp12 enables mutant selective targeting of K-Ras-G12D.Nat Chem Biol2024https://conductscience.org/library/papers/38443470PubMed
38066554Antitumor effect of a small-molecule inhibitor of KRASG12D in xenograft models of mucinous appendicular neoplasms.Exp Hematol Oncol2023https://conductscience.org/library/papers/38066554PubMed
37831007A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer.Clin Cancer Res2024https://conductscience.org/library/papers/37831007PubMed
37509345Ability of 18F-FDG Positron Emission Tomography Radiomics and Machine Learning in Predicting KRAS Mutation Status in Therapy-Naive Lung Adenocarcinoma.Cancers (Basel)2023https://conductscience.org/library/papers/37509345PubMed

Download CSV of cited by

Genes8

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37339170

GET https://conductscience.org/api/papers/v1/37339170/authors